All In MedTech

FDA Clearance Tracker · P150010-S005

HYMOVIS ONE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 9, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 9, 2025

Approved

Time to decision

107 days

Received Dec 23, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150010-S005
Device name
HYMOVIS ONE
Applicant location
Abano Terme
Received
Dec 23, 2024
Decided
Apr 9, 2025
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150010

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

HYMOVIS® ONE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

Source documents

Other decisions for Fidia Farmaceutici

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.